Woburn, MA – February 21, 2024CONTINUUS Pharmaceuticals, a cutting-edge pharmaceutical firm specializing in end-to-end integrated continuous manufacturing, is pleased to announce the appointment of William S. Marth, RPh., MBA to its esteemed Board of Directors. 

Mr. Marth brings over three decades of invaluable experience in the global pharmaceutical industry. His deep understanding of the industry is pivotal in ensuring a successful cGMP commercial implementation of CONTINUUS technology and makes him an ideal addition to CONTINUUS’s leadership team. 

It is an exciting opportunity to join the Board of CONTINUUS, a leader in integrated continuous manufacturing of pharmaceuticals. Continuous manufacturing is an important strategic initiative for the pharmaceutical industry and robustness of global supply chains.” said Mr. Marth. 

Mr. Marth serves as the Managing Partner of North Ocean Ventures, LLC as well as President of Services at National Resilience. Prior to that, Mr. Marth led the take private of AMRI now Curia (Nasdaq AMRI) in September of 2017 in a $1.6 billion-dollar transaction after a series of 7 acquisitions in 4 years to build one of the top 5 Global CDMOs. A Director of the company since 2012, Mr. Marth served as President and Chief Executive Officer of AMRI since 2014. He also served as Chairman of the Board in 2013. Prior to joining AMRI, Mr. Marth served as President and CEO of Teva Pharmaceutical Industries Ltd. for the Americas’. 

Salvatore Mascia, Chief Executive Officer of CONTINUUS, expressed enthusiasm about Mr. Marth’s appointment: “Having signed several development contracts with major pharma companies, we are at a key stage in the launch of our commercial supply activities, therefore we considered expanding our Board with the necessary skill set to accomplish this goal. Mr. Marth is undoubtedly the ideal industrial executive to guide us into this new phase of the company. I feel honored to have the opportunity to work and learn from his deep knowledge and experience”.  

Click here for the full press release